Skip to main content

and
  1. Article

    Open Access

    Fludarabine plus reduced-intensity busulfan versus fludarabine plus myeloablative busulfan in patients with non-Hodgkin lymphoma undergoing allogeneic hematopoietic cell transplantation

    Allogeneic hematopoietic cell transplantation (HCT) offers a possible cure for patients with relapsed and refractory non-Hodgkin lymphoma (NHL) through potentially beneficial graft versus lymphoma effects. How...

    Kimimori Kamijo, Yoshimitsu Shimomura, Akihito Shinohara in Annals of Hematology (2023)

  2. No Access

    Article

    Resignation and return to work in patients receiving allogeneic hematopoietic cell transplantation close up

    To characterize the issues regarding work and employment specific to allogeneic hematopoietic cell transplantation (allo-HCT) survivors, we conducted a nationwide cross-sectional questionnaire survey.

    Saiko Kurosawa, Takuhiro Yamaguchi, Ayako Mori in Journal of Cancer Survivorship (2022)

  3. No Access

    Article

    Expression of activated integrin β7 in multiple myeloma patients

    Multiple myeloma (MM) is still extremely difficult to cure, and new therapeutic drugs are needed. We recently found that integrin β7 is constitutively activated in MM cells, and chimeric antigen receptor (CAR)...

    Naoki Hosen, Satoshi Yoshihara, Hiroyuki Takamatsu in International Journal of Hematology (2021)

  4. No Access

    Article

    The prognostic impact of FLT3-ITD, NPM1 and CEBPa in cytogenetically intermediate-risk AML after first relapse

    We evaluated the impact of FLT3-ITD, NPM1 mutations, and double mutant CEBPa (dmCEBPa) on overall survival (OS) after relapse in patients with cytogenetically intermediate-risk acute myeloid leukemia (AML) who we...

    Saiko Kurosawa, Hiroki Yamaguchi, Takuhiro Yamaguchi in International Journal of Hematology (2020)

  5. Article

    Open Access

    A prospective trial of vaccine to prevent hepatitis B virus reactivation after hematopoietic stem cell transplantation

    Hepatitis B virus (HBV) reactivation reportedly occurs frequently after hematopoietic stem cell transplantation (HSCT) in resolved HBV-infected patients. Here, 50 patients with resolved HBV infections and sche...

    Koji Nishikawa, Kiminori Kimura, Yoshinobu Kanda in Bone Marrow Transplantation (2020)

  6. No Access

    Article

    Clinical effects of recombinant thrombomodulin and defibrotide on sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation

    Sinusoidal obstruction syndrome (SOS) is a lethal complication after hematopoietic stem cell transplantation (HSCT). Defibrotide (DF) is the only drug internationally recommended for SOS treatment in Western c...

    Kimikazu Yakushi**, Takayuki Ikezoe, Chikako Ohwada in Bone Marrow Transplantation (2019)

  7. No Access

    Article

    Employment status was highly associated with quality of life after allogeneic hematopoietic cell transplantation, and the association may differ according to patient age and graft-versus-host disease status: analysis of a nationwide QOL survey

    Saiko Kurosawa, Takuhiro Yamaguchi, Kumi Oshima in Bone Marrow Transplantation (2019)

  8. No Access

    Article

    Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

    An 11q23 abnormality presents in approximately 5% of adults with acute myeloid leukemia (AML) and is associated with adverse outcomes even after allogeneic hematopoietic cell transplantation (allo-HCT). To eva...

    Takaaki Konuma, Shohei Mizuno, Tadakazu Kondo, Hiroki Yamaguchi in Annals of Hematology (2018)

  9. No Access

    Article

    Early lymphocyte recovery predicts clinical outcome after HSCT with mycophenolate mofetil prophylaxis in the Japanese population

    Immune reconstitution affects clinical outcomes after allogeneic hematopoietic stem cell transplantation (HSCT), and it has been suggested that lymphocyte recovery affects survival after HSCT. However, few stu...

    Keiji Kurata, Kimikazu Yakushi**, Ishikazu Mizuno in International Journal of Hematology (2018)

  10. No Access

    Article

    D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations

    The clinical impact of KIT mutations in core binding factor acute myeloid leukemia (CBF-AML) is still unclear. In the present study, we analyzed the prognostic significance of each KIT mutation (D816, N822K, and ...

    Shunsuke Yui, Saiko Kurosawa, Hiroki Yamaguchi, Heiwa Kanamori in Annals of Hematology (2017)

  11. No Access

    Article

    A prospective study of the antiemetic effect of palonosetron in malignant lymphoma patients treated with the CHOP regimen

    To identify strategies for reducing emesis induced by the CHOP regimen, which includes high-dose steroids, we prospectively evaluated the efficacy of palonosetron in Japanese patients. Palonosetron was adminis...

    Yoshiharu Miyata, Kimikazu Yakushi**, Yumiko Inui in International Journal of Hematology (2016)

  12. No Access

    Article

    Phase I/II study of tandem high-dose chemotherapy with autologous peripheral blood stem cell transplantation for advanced multiple myeloma

    The efficacy and safety of high-dose chemotherapy with tandem autologous peripheral blood stem cell transplantation (auto-PBSCT) were evaluated in a multicenter clinical study of patients with advanced multipl...

    Kazutaka Sunami, Katsuji Shinagawa, Morio Sawamura in International Journal of Hematology (2009)

  13. No Access

    Article

    Total body irradiation followed by bone marrow transplantation: comparison of once-daily and twice-daily fractionation regimens

    The purpose of this study was to evaluate the results of two sequential total body irradiation (TBI) regimens, especially focusing on pulmonary complications.

    Toshinori Soejima, Saeko Hirota, Kayoko Tsu**o, Eisaku Yoden in Radiation Medicine (2007)